Genmab A/S (GMAB)
34.35
+1.33
(+4.03%)
USD |
NASDAQ |
Aug 25, 16:00
34.35
0.00 (0.00%)
After-Hours: 19:59
Genmab Net Income (Quarterly) : 302.57M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 302.57M |
| March 31, 2026 | 53.20M |
| December 31, 2025 | 30.98M |
| September 30, 2025 | 399.18M |
| June 30, 2025 | 340.52M |
| March 31, 2025 | 195.13M |
| December 31, 2024 | 549.88M |
| September 30, 2024 | 186.41M |
| June 30, 2024 | 203.20M |
| March 31, 2024 | 192.88M |
| December 31, 2023 | 92.29M |
| September 30, 2023 | 307.12M |
| June 30, 2023 | 195.03M |
| March 31, 2023 | 30.27M |
| December 31, 2022 | 80.03M |
| September 30, 2022 | 349.41M |
| June 30, 2022 | 270.52M |
| March 31, 2022 | 70.11M |
| December 31, 2021 | 110.04M |
| September 30, 2021 | 141.07M |
| June 30, 2021 | 49.61M |
| March 31, 2021 | 177.50M |
| December 31, 2020 | 93.06M |
| September 30, 2020 | 83.21M |
| June 30, 2020 | 498.80M |
| Date | Value |
|---|---|
| March 31, 2020 | 39.66M |
| December 31, 2019 | 218.11M |
| September 30, 2019 | 80.01M |
| June 30, 2019 | 12.77M |
| March 31, 2019 | 10.99M |
| December 31, 2018 | 127.51M |
| September 30, 2018 | 27.95M |
| June 30, 2018 | 41.65M |
| March 31, 2018 | 32.77M |
| December 31, 2017 | 124.31M |
| September 30, 2017 | -0.8972M |
| June 30, 2017 | 45.50M |
| March 31, 2017 | 2.308M |
| December 31, 2016 | 121.89M |
| September 30, 2016 | 28.34M |
| June 30, 2016 | 25.53M |
| March 31, 2016 | -1.703M |
| December 31, 2015 | 57.14M |
| September 30, 2015 | 20.89M |
| June 30, 2015 | 2.444M |
| March 31, 2015 | 32.79M |
| December 31, 2014 | 11.59M |
| September 30, 2014 | 28.43M |
| June 30, 2014 | -4.805M |
| March 31, 2014 | 18.09M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Ascendis Pharma A/S | 240.65M |
| Zealand Pharma A/S | 609.41M |
| Bavarian Nordic A/S | 113.83M |
| Evaxion AS | -3.724M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.153B |
| Total Expenses (Quarterly) | 850.79M |
| EPS Diluted (Quarterly) | 0.4903 |
| Enterprise Value | 23.48B |
| Gross Profit Margin (Quarterly) | 92.73% |
| Profit Margin (Quarterly) | 26.23% |
| Earnings Yield | 3.68% |
| Operating Earnings Yield | 6.09% |
| Normalized Earnings Yield | 4.486 |